

## Siemens Healthineers adds Lung Cancer to its Al Pathway Companion



Siemens Healthineers recently added non-small cell lung cancer support to its AI Pathway Companion. Currently supported pathways are non-small cell lung and prostate cancer.

Siemens first presented its Al Pathway Companion at the 2018 Annual Meeting of the Radiological Society of North America in Chicago. In summary, the system delivers artificial intelligence (Al)-supported clinical decision support (CDS) for physicians making diagnostic and treatment decisions along specified clinical pathways so that physician teams can better manage patient care and case reviews. The system organises patient information in a single dashboard, quality checks data completeness, and permits relevant notations in the patient documentation. It updates the physician team on the patient's clinical status and advises on treatment next steps according to established healthcare guidelines. The tool also facilitates inter-department collaboration by sharing information across interdepartmental care teams.

In the near future, Siemens Healthineers intends include more disease parameters in the clinical pathway, and in turn increase the relevant data points the CDS tool has for determining the next steps in care. The company plans to partner with healthcare institutions that want to incorporate the Al-Pathway Companion into their routine clinical service and lung cancer workflow.

The University of Missouri Health Care is one partner institution that recently incorporated the Al-Pathway Companion for Prostate Cancer. To incorporate CDS systems into the organisational workflow, Dr Mark Wakefield, Chief of Urology at the University of Missouri Health Care, offered advice below based on their institution's experience:

- Let clinicians champion the CDS system's benefits for patients and the provider.
- Partner with a CDS solution provider that can provide long-term support.

Image Source: Siemens Healthineers

Published on: Thu, 14 Oct 2021